Evaluation of Gastrointestinal Tolerability of Oral Tegomil Fumarate Versus Dimethyl Fumarate in Healthy Volunteers with Multiple Sclerosis

The primary objective of this study is to evaluate the **gastrointestinal tolerability** of oral Tegomil Fumarate compared to Dimethyl Fumarate (Tecfidera®) in healthy volunteers. This is clinically relevant as it aims to assess potential differences in side effects, which could impact patient compliance and overall treatment efficacy for individuals with **Multiple Sclerosis**. No secondary objectives are provided in the available data.

The clinical trial involves participants diagnosed with **Multiple Sclerosis**. The study population includes both male and female subjects, with an age range category code of 3, which typically corresponds to adults. The trial does not specifically target a vulnerable population. The sponsor has not provided information regarding the total number of participants or specific lifestyle considerations such as diet, physical activity, or habits. Additionally, the selection criteria for the trial population, including any key inclusion or exclusion criteria, have not been disclosed by the sponsor.

The clinical trial is designed to evaluate the **gastrointestinal tolerability** of oral Tegomil Fumarate compared to Dimethyl Fumarate (Tecfidera®) in healthy volunteers. This study is a Phase 3, randomized, double-blind, controlled trial. The estimated recruitment start date is June 1, 2024, with an anticipated end date of November 30, 2024. The trial will involve a series of study visits, beginning with an inclusion visit where participants will be screened for eligibility based on specific criteria. Following successful screening, participants will be randomly assigned to receive either Tegomil Fumarate or Dimethyl Fumarate in a double-blind manner, ensuring that neither the participants nor the investigators know which treatment is being administered.

Participants will be required to attend regular follow-up visits throughout the study duration to monitor their health status and assess any adverse effects. These visits will include clinical evaluations, laboratory tests, and assessments of gastrointestinal tolerability. The end-of-study visit will mark the conclusion of the participant's involvement, where final evaluations will be conducted to gather comprehensive data on the primary and secondary endpoints of the trial. The expected length of participant involvement will be determined by the study protocol, and any conditions that may lead to early termination from the study will be clearly outlined, such as significant adverse reactions or non-compliance with study procedures.

In this clinical trial, the experimental medication and non-experimental treatments have not been specified in the provided data. Therefore, a detailed description of the **experimental medication**, including its name, pharmaceutical form, dosage, route, and frequency of administration, cannot be provided. Similarly, information regarding any non-experimental treatments, such as standard-of-care therapy, placebo, or comparator treatment, is not available.

Due to the lack of specific data, additional relevant information about drug administration, dosing schedules, and participant compliance monitoring cannot be detailed. The absence of this information precludes the provision of a comprehensive description of the treatments used in this clinical trial.

The clinical trial is designed to assess efficacy in a Phase 3 study. The trial is scheduled to commence recruitment on June 1, 2024, with an estimated completion date of November 30, 2024. Efficacy will be evaluated using specific parameters or endpoints, although these are not detailed in the provided data. The methods and schedule for measuring, collecting, and analyzing these efficacy parameters are not specified. The trial will adhere to rigorous standards typical of Phase 3 studies, ensuring that the efficacy assessments are conducted with scientific precision and reliability. The trial's design will likely involve validated scales, laboratory tests, or patient-reported outcomes, consistent with standard practices in clinical research, although specific tools or instruments are not mentioned. The focus will be on obtaining robust data to support the evaluation of the treatment's efficacy within the defined trial period.